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Needle acquisition patterns, network risk
and social capital among rural PWID in
Puerto Rico
Ian Duncan1* , Patrick Habecker1, Roberto Abadie1, Ric Curtis2, Bilal Khan1 and Kirk Dombrowski1
Abstract
Background: People who inject drugs (PWID) take on significant risks of contracting blood-borne infection,
including injecting with a large number of partners and acquiring needles from unsafe sources. When combined,
risk of infection can be magnified.
Methods: Using a sample of PWID in rural Puerto Rico, we model the relationship between a subject’s number of
injection partners and the likelihood of having used an unsafe source of injection syringes. Data collection with 315
current injectors identified six sources of needles.
Results: Of the six possible sources, only acquisition from a seller (paid or free), or using syringes found on the
street, was significantly related to number of partners.
Conclusions: These results suggest that sources of syringes do serve to multiply risk of infection caused by multi-
partner injection concurrency. They also suggest that prior research on distinct forms of social capital among PWID
may need to be rethought.
Background
It is often taken for granted that people who inject drugs
take on significant risks of infection. In addition to the
potentially harmful effects that injecting drugs can have
in and of itself, there is also the additional concern of
spreading disease through the sharing of needles or
other equipment—such as syringes, cookers, or cotton
used to filter the solution before it is drawn into the syr-
inge. Despite these risks, people who inject drugs
(PWID) often share injection equipment, both as a cost-
cutting measure [1] and as a way to establish and main-
tain relationships [2]. This risk behavior has received
considerable attention in the past—resulting in early and
consistent efforts by syringe exchange and syringe ser-
vice programs since the 1980s [3]. The success of such
harm reduction programs is clear [4], but recent work
has shown a dearth of services in rural areas [5]. The
aim of this paper is to examine how, for rural PWID, the
number of risk partners in an individual’s injection
network influences or is influenced by where they ob-
tained their injection syringes.
Understanding the unique risks associated with rural
injection is significant; the last 10 years have shown a
dramatic rise in rural injection drug use [6, 7]. Rural syr-
inge access programs face large challenges, most espe-
cially the difficulty they face in reaching a highly
dispersed population [8]. Under these circumstances, at-
tention to the ongoing risk posed by risky syringe access
is critical.
There are a number of sources from which both rural
and urban PWID acquire syringes, such as syringe ex-
change programs, pharmacies, or the secondary market
(e.g., drug sellers, other injectors, etc.). Each of these
sources comes with its own unique constellation of risks
based on how likely the syringe received is to be steri-
le—from certainly sterile syringes obtained via pharma-
cies and exchanges that carry no risk to highly risky,
potentially contaminated syringes found on the street.
Not all PWID have equal access to these sources. Social
constraints influence syringe access in many rural areas,
especially where formal syringe exchange programs re-
main illegal [9]. Where rural pharmacies have the
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potential to fill this gap, research has shown consider-
able variability in the receptiveness of pharmacies to
serve the PWID population [10]. Under such conditions,
syringe access sources do not necessarily reflect choices
by drug users, at least in any strict sense. Rather, infor-
mation on syringe access also (and perhaps only) points
to ways in which access to sterile injection equipment
may be decided by larger structural factors, such as syr-
inge availability and the presence or absence of individ-
ual social capital [11]. In this sense, a focus on syringe
sources may best be understood as a study of the extent
to which the structural issues that govern users lives po-
tentially limit their opportunities to engage in safe injec-
tion practices, putting the larger community of drug
users (and the community in which those users are em-
bedded) at risk of infection [12].
The range of strategies for obtaining injection-related
syringes is large, though most of our information on the
topic comes from research in urban areas. In large US
cities, buying a syringe on the secondary market is a
common means of acquisition [4, 13]. For example, Lat-
kin and Forman [14] examined PWID in Baltimore, find-
ing that designated sellers were, by far, the most
common source of syringes for their sample. This is a
worrisome finding, as participants who sold needles and
syringes reported that it was easy to make used equip-
ment appear new, and some admitted to reselling re-
selling used syringes, while others implied this practice
was common though they did not do it. In all, only 8%
of respondents in this study reported using exclusively
safe sources [14]. These were predominately from the
formal market (exchanges, pharmacies, and hospitals; we
note that secondary exchange with an insulin-injecting
diabetic was considered a safe source in their research).
Other urban studies have found that access to ex-
change programs or other methods of generally safer ac-
cess, such as pharmacies, decreased needle and syringe
sharing among PWID [15–17]. Research by Fuller and
colleagues [18] found that needle/syringe access pro-
grams did not lead to more unsafely discarded syringes
in the neighborhood, as some opponents worried. How-
ever, research from Iran found that insufficient access to
an exchange program was associated with more needle
and syringe re-use [19], and similar research in US cities
found that use of exchange programs was associated
with decreased equipment sharing overall, though the
relationship was fairly weak [20].
Craine and colleagues [21] compared respondents’ pat-
terns of pharmacy-based purchases, non-pharmacy-
based exchanges, or use of the secondary market (e.g.,
street sellers), and found distinctive user profiles based
on source frequencies. For example, PWID who typically
used non-pharmacy exchanges had higher injection fre-
quencies and were more likely to be homeless, whereas
those who typically used the secondary market were
comparatively younger and more recent initiators of in-
jection drug use than their peers. These findings suggest
that, while exchange programs are beneficial, they do
not necessarily reach across all user groups, leaving dis-
tinct sets of drug users with much higher risk profiles
than others.
The impact of rurality on the use of safe injection
equipment has received less attention. Recent work by
our study team found that, in both rural and urban
Puerto Rico, utilizing syringe exchange programs signifi-
cantly increases the frequency of using sterile equipment
to inject [8] and that rural users faced significantly lower
access to exchange programs. Other research on rural
drug use suggests that syringe sharing remains common,
despite the prevalence of safer options [22].
Despite the above findings, basic demographic vari-
ables have shown mixed results as predictors of syringe
access patterns. For example, studies examining the role
of gender on syringe acquisition show more risky injec-
tion behaviors among women, such as needle borrowing
[23] and equipment sharing in general [24], but also
finding that women are less likely to use the secondary
market as a source of syringes [25]. Age has been identi-
fied as a generally reliable factor for syringe source risk,
concluding that younger injectors exhibiting more
injection-related risks than older injectors [26–28]. This
includes research using an urban Australian sample that
found that among young people transitioning to injec-
tion, there was little knowledge about sources of safe in-
jection equipment [29]. For LGB respondents, however,
it was those without stable housing who were more
likely to use the secondary market of friends and sellers
[30]. Craine et al. [21] found just the opposite—that
homelessness was positively related to preferring the for-
mal market, such as non-pharmacy exchanges, and
avoiding riskier sources. Furthermore, some research
finds that, when choice is possible, the preferred source
is related to individual tendencies to share equipment
[31], whereas others find no such relationship [30].
While PWID in most studies are predominately low-
income [32], income differential has been shown to
affect syringe-related risk behaviors: higher-income
PWID are more likely to take protective measures when
they inject, such as only selecting partners with similar
viral statuses [33]. Conversely, research in Iran found
that homeless participants were more likely than those
with stable housing to access needles on the secondary
market [34].
While the demographics of users have been shown to
hold some predictive power in understanding structural
factors that affect injection risk, it is important to con-
sider an additional potential predictor: risk network size.
Prior studies have analyzed the risk of sharing syringes
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in networks, but few have examined syringe acquisition
behavior in relation to overall co-injector network de-
gree [34]. More common are studies that examine social
support in regulating sharing [35] or network topological
factors that influence transmission of infection across
whole networks [36–39]. While some have examined the
link between personal network size and syringe sharing
behaviors [40], as far as we know, no one has looked at
the relationship between personal network size and syr-
inge access.
In what follows, we treat personal network size as a
risk behavior [41, 42]. By examining the number of users
with whom one has shared syringes, we make use of a
quantitative measure that is closely tied to both individ-
ual risk of infection and overall network topology [43,
44]. If a positive association is found between network
size and use of unsafe sources for syringes, the system-
wide importance of individual acts rises significantly [38,
45]. For these reasons, examining the relationship be-
tween co-injection network size and a range of syringe
acquisition sources is an important next step in under-
standing structural and personal network factors related
to injection risk.
In the analysis below, we test the hypothesis that those
who inject with more partners will be more likely to de-
pend on syringes from higher risk sources. There are
reasons to believe such a relationship will exist. Both of
these factors can be seen to involve questions of limited
resources, venue-based limited opportunities (as when
drug use takes place in a shooting gallery), and a reliance
on long-term social relationships. In addition, ethno-
graphic fieldwork at our research locale pointed to im-
portant social dynamics that influence syringe needs and
the relationships that can meet those needs. Mixed
qualitative and quantitative analyses have shown that in
rural Puerto Rico, co-injection network size is correlated
with frequency of drug use—an outgrowth of the fact
that frequent users require more opportunities for
collaborating in a local injection practice known as
caballo [46]. In rural Puerto Rico, caballo involves two
PWID pooling financial resources to obtain both heroin
and cocaine for mixed injection (known in the drug
literature as a “speedball”), with the two caballo partners
then sharing the combined drugs. This is a favored local
form of injection, particularly among frequent users in
rural Puerto Rico where it will sometimes be performed
ten or more times each day. By pooling resources, users
can get ½ bag of heroin and ½ bag of cocaine for roughly
what it would cost them for a whole bag of one or the
other.
The main use of a low-dose speedball in this way is
stave off withdrawal while counteracting the soporific ef-
fects of the heroin, leaving the user sufficiently func-
tional to go about the task of daily life. Frequent
injectors tend to maximize the size of their co-injection
network to allow greater opportunities for pooling/shar-
ing of resources. Yet, higher rates of injection also imply
the need for a higher number of syringes. Given the lim-
ited time available between uses prior to experiencing
withdrawal, such practices suggest that those with high
frequency of use and high numbers of partners would
more regularly resort to less safe sources for injection
equipment. This logic is supported by ethnographic evi-
dence from our study which noted that high-frequency
users were likely to rely on exchange programs for some
of their syringes, but that the high number required for
multiple daily use (often exceeding 10 times per day)
meant that the number of syringes received from SEPs
will not be enough for their needs. Re-using or buying
from peers or from drug sellers was a common strategy
to make up the difference. Such strategies, however,
magnify overall risk of infection, coupling the number of
concurrent partners with increasing use of unsafe injec-
tion equipment. Our hypothesis is meant to reflect this
possibility. We make this prediction with caution, how-
ever, as previous analyses found that PWID behaviors
are strongly influenced by local norms governing injec-
tion equipment sharing and overall injection practices
[47]. In addition, we utilize a sample of rural Puerto
Rican PWID, and there is evidence that urban Puerto
Rican injectors have higher rates of syringe sharing more
generally [48] and on average inject more frequently [49]
than PWID on the US mainland. Furthermore, rural
PWID are less influenced by infection status of potential
co-users when selecting co-injection partners [50].
Data
Interviews with 315 participants were completed be-
tween April 19 and June 15, 2015, in a rural area ap-
proximately 30 miles from San Juan, Puerto Rico,
drawing participants from several surrounding towns.
Eligible participants were alert, 18 years of age or older,
and reported injecting drugs within the last 30 days. Vis-
ual inspections for injection signs as well as question-
naires about drug injection knowledge were used to
confirm this. Upon completing the questionnaire, partic-
ipants were compensated with $25. Recruitment into the
sample was managed using Respondent-Driven Sampling
(RDS) whereby participants who completed the survey
were given three referral coupons that they could pass
out to other qualified individuals who had not previously
participated in the project. Recruitment began with eight
total seeds, two from each community in the area. For
every referral that completed the survey, the referee
could earn an additional $10. RDS is often the preferred
method for recruiting stigmatized populations and has a
strong track record for reliable results when used to pro-
duce samples of PWID [51–53]. Seeds were identified
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through a local, mobile, weekly syringe exchange pro-
gram. Though there are concerns about representative-
ness using this method of recruitment, analyses of the
sampling bias show low levels of demographic or injec-
tion behavior homophily and minimal degree effects in
the recruitment process [54, 55]. Analysis of referral data
showed that past participation in drug treatment had
more of an effect on network ties than other factors, and
use/non-use of syringe exchange did not seem to have a
marked influence on recruitment patterns.
The questionnaire itself was interviewer-administered
and based on the CDC National HIV Behavioral Surveil-
lance (NHBS) IDU (injection drug use) Round 3 Ques-
tionnaire, version 3. The instrument asked questions
about injection behavior, hepatitis C (HCV) and HIV sta-
tus and testing histories, and several other topics related
to drug use and HIV/HCV risk. In addition to recording
the participants’ self-reported HCV and HIV status prior
to participating in the study, the project provided rapid
testing for both HIV and HCV using INSTI Rapid HIV
antibody tests (Biolytical Laboratories) and OraQuick
HCV Rapid antibody tests (OraSure Technologies). Par-
ticipants were compensated an additional $5 for each
test completed. Participants who tested positive for
HCV or HIV were offered referral and transportation to
a primary care doctor for confirmatory testing and po-
tential treatment. The study received IRB approval
through the University of Nebraska-Lincoln (IRB#
20131113844FB) and the University of Puerto Rico
School of Medicine (IRB# A8480115).
Methods
We use six distinct dependent variables, each corre-
sponding to whether or not the participant had acquired
a needle from a specific source over the past year. These
six sources are (1) a syringe exchange program; (2) a
local pharmacy; (3) free from a friend, acquaintance,
relative, or sex partner; (4) free from someone else, such
as their dealer or gallery operator; (5) paid for a syringe
from a dealer, shooting gallery operator, or other ven-
dors on the street; and (6) found a syringe on the street.
These questions were asked independently, and respon-
dents answered yes or no. Exchange programs and phar-
macies can be thought of as the formal market, whereas
the other sources reside on the secondary market.
Unfortunately, the data includes no information on the
number of syringes obtained in the past year from each
location, just if the source was used or not. In the
survey, users were allowed to answer yes or no for each
category but were not asked to rank the list of possible
sources. For this reason, each source is analyzed
individually.
Our primary independent variable is the number of
partners a respondent had co-injected with and used the
syringe after their partner did, over the past year. This is
a highly restrictive notion of injection partner—one with
whom a respondent has participated in an injection be-
havior that risks —that is meant to ensure we are asses-
sing actual infection risk when using the measure as a
statistical predictor of accessing syringes from a particu-
lar source. Respondents were asked, “In the last 12
months, with how many people did you use a needle
after they injected with it?” This is an important distinc-
tion from simply number of caballo or other risk part-
ners, as the risk of viral infection is inherently larger for
people who inject second.
Several control variables were used in this analysis.
These included (1) marital/co-habitation status (1 =
married/cohabitating, 0 = single/other); (2) if participant
annual income was $5000 or more (yes = 1); (3) gender
(1 = male, 0 = female); (4) age; (5) age at first injection;
(6) homeless in the past year (yes = 1); (7) and ordinal
measure of injection frequency (1 = 1–3 times/month, 2
= 1–6 times/week, 3 = 1–3 times/day, 4 = 4+ times/
day); (8) HCV status (dummy variable, with “unknown”
as the omitted category); and (9) HIV status (dummy
variable, with “unknown” as the omitted category).
We ran six models, one for each syringe source. In the
model with “found needle on the street” as the source,
gender and HCV status were removed from the model
because they contain zero counts for each of these cells.
A number of the initial controls were found to be insig-
nificant, and additional condensed models were run for
each source without them. Both sets of regression ana-
lyses are reported below. Though our total sample in-
cluded 315 respondents, our analytical sample here is
smaller (n = 245). Cases were removed due to missing
data on at least one measure used across the models.
Descriptive statistics of the analytic sample can be found
in Table 1.
Results
Among the six syringe acquisition sources examined
(Tables 2, 3, 4, 5, 6 and 7), only the three riskiest were
significantly associated with number of injection part-
ners in the full model: using a syringe found on the
street (Table 7), buying a syringe from a seller (Table 6),
and receiving a free syringe from a seller (Table 5). For
each additional injection partner, a respondent had, their
odds of having using a syringe found on the street in-
creased by a factor of 1.282 (CI 1.051, 1.563). For each
additional partner, the odds of having bought a syringe
from a seller in the past year increased by a factor of
1.260 (CI 1.022, 1.552) compared to having not bought
from their sellers. Finally, for each additional co-
injection partner, the odds of having used a free needle
from a seller increased by a factor of 1.346 (CI 1.110,
1.632). Among our control variables, none were
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consistently associated across all six possible options,
though several had a significant relationship with one or
more needle source. These relationships include:
 Higher injection frequencies (though not higher
number of risk partners) were associated with
having used a needle exchange program in the past
year, as was having a HCV+ status (Table 2). For
each unit increase on the 4-level injection frequency
scale used, respondents were 1.688 (CI 1.197, 2.381)
times as likely to have used a needle exchange in the
past year. Respondents who had contracted the
hepatitis C virus were 2.128 (CI 1.032, 4.385) times
as likely to have used an exchange in the past year
compared to their peers without HCV or who’s
HCV status was unknown.
 Neither our main independent variable nor any of
our controls were found to be significant predictors
for using a pharmacy as a source (Table 3). This was
the only source that had no significant predictors.
 Obtaining needles through friends and relatives was
only associated with current age (Table 4). For each
additional year, the odds of a respondent having
used a syringe obtained from a friend or family
member decreased by a factor of 0.967 (CI 0.937,
0.998).
 In addition to our main independent variable,
respondents who were homeless during the past
year were more likely to have used a free syringe
from a seller. Conversely, those with a confirmed
HCV− status were less likely, as were respondents
with a confirmed HIV+ status. However, these were
only marginally significant relationships.
 Finally, no control variables were significant
predictors for either using a syringe bought from a
seller or using one found on the street.
Additional condensed models were conducted for
each source using only the variables that were signifi-
cant or marginally significant predictors in the full
model. In all but one case, the results were the same.
The lone exception was the condensed model for
Table 1 Descriptive statistics
Variables Percent/
mean
Standard dev Min Max
Syringe Sources, past year:
From exchange 56.33% 0 1
From pharmacy 32.24% 0 1
From friends/family 32.65% 0 1
From seller (paid) 54.29% 0 1
From seller (free) 13.06% 0 1
From the street 4.05% 0 1
Total number of co-injection
partners, past year (binned at 15+)
0.857 2.006 0 15
Married/living with partner 23.67% 0 1
Annual income of $5000+ 21.22% 0 1
Male 89.39% 0 1
Current age (binned at 70+) 41.873 10.162 18 70
Age at first injection 22.082 8.331 11 58
Homeless, past year 38.54% 0 1
Injection frequency 3.184 0.822 1 4
1–3 times a month (1) 5.71%
1–6 times a week (2) 8.98%
1–3 times a day (3) 46.53%
4+ times a day (4) 38.78%
HCV status
Positive 52.24% 0 1
Negative 26.53% 0 1
Unknown 21.22% 0 1
HIV status
Positive 4.08% 0 1
Negative 83.27% 0 1
Unknown 12.65% 0 1
Table 2 Two-tailed binary logistic regression on needle
source: exchange
OR
(full)
CI *** OR
(condensed)
CI ***
Number of injection
partners
0.998 0.872,
0.142
0.989 0.869,
1.126
Married/cohab 0.892 0.467,
1.705
Income over $5000 1.285 0.647,
2.552
Male 0.911 0.369,
2.247
Age now 1.010 0.980,
1.040
Age, first injection 1.003 0.968,
1.039
Homeless, past year 0.923 0.513,
1.661
Injection frequency 1.688 1.197,
2.381
** 1.577 1.140,
2.182
**
HCV status+ 2.128 1.032,
4.385
* 2.073 1.057,
4.064
*
HCV status− 2.117 0.936,
4.785
1.935 0.905,
4.134
HIV status+ 2.314 0.353,
15.175
HIV status− 0.547 0.227,
1.198
N = 245
P values: *** ≥ 0.001; ** ≥ 0.01; * ≥ 0.05; + ≥ 0.1
Duncan et al. Harm Reduction Journal  (2017) 14:69 Page 5 of 11
using a syringe given to you for free from a seller.
None of the marginally significant predictors from the
full model retained any predictive power in the con-
densed model, suggesting a confounding effect.
Discussion
Of the six potential sources, only the three riskiest were
associated with having a larger co-injection network
size. These included (1) buying a syringe from a seller,
(2) using a free syringe from a seller, and (3) using a
syringe found on the street. These findings raise ques-
tions about the social structural factors that condition
syringe access. Foremost among these is the question of
the relationship between co-injectors: presumably,
PWID with larger co-injection networks would have
more opportunities to acquire syringes from friends
who they inject with, yet we found no evidence of such
a relationship. In considering the importance of this
finding, it is important to recognize that, while syringe
sharing behaviors are often conceived of as involving
decisions or choices by individuals, user decisions are
conditioned by the range of syringe access opportun-
ities and their limits. One can only make the decision
to use a sterile equipment if one has access to it. In the
absence of a full range of choices, what may appear like
modifiable behaviors may not be nearly so malleable.
Rather than reading the results of this analysis as a
reflection on individual choices, decisions, or behaviors
[56, 57]—an interpretation that would be possible only
where everyone has equal access to all possible
sources—we instead consider these results as a reflec-
tion of the social capital of rural PWID as it is
expressed in their injection behaviors, including syringe
acquisition [11, 29].
Such a finding points to an important distinction in
risk-related social determinants of health: that forms of
social capital associated with drug access do not neces-
sarily reflect greater social capacity for risk reduction.
Social connections have been implicated as an important
source of social capital among PWID [58–61], including
recent research that has drawn attention to what has
been referred to (unfortunately) as “negative” social capi-
tal—patterns of connection that draw individuals into
more high-risk situations [12]. In the latter case, risk-
reducing connections such as those providing social sup-
port are balanced by other relationships with less salu-
brious outcomes [11]. In rural Puerto Rico, this
relationship between having a high number of risk
Table 3 Two-tailed binary logistic regression on needle
source: pharmacy
OR
(full)
CI *** OR
(condensed)
CI ***
Number of injection
partners
0.949 0.813,
1.108
0.941 0.809,
1.095
Married/cohab 0.899 0.457,
1.770
Income over $5000 1.038 0.513,
2.100
Male 0.686 0.283,
1.664
Age now 1.021 0.990,
1.052
Age, first injection 0.985 0.950,
1.021
Homeless, past year 0.946 0.514,
1.739
Injection frequency 1.058 0.751,
1.491
HCV status+ 0.708 0.337,
1.490
HCV status− 1.146 0.505,
2.603
HIV Status+ 1.555 0.311,
7.770
HIV Status− 1.082 0.442,
2.648
N = 245
P values: *** ≥ 0.001; ** ≥ 0.01; * ≥ 0.05; + ≥ 0.1
Table 4 Two-tailed binary logistic regression on needle source:
friend or relative
OR
(full)
CI *** OR
(condensed)
CI ***
Number of injection
partners
1.008 0.876,
1.160
1.006 0.879,
1.151
Married/cohab 0.843 0.426,
1.670
Income over $5000 1.908 0.948,
3.841
Male 0.544 0.224,
1.318
Age now 0.967 0.937,
0.998
* 0.967 0.941,
0.994
*
Age, first injection 1.014 0.977,
1.053
Homeless, past year 1.422 0.762,
2.651
Injection frequency 0.838 0.592,
1.187
HCV Status+ 0.743 0.352,
1.568
HCV Status− 0.861 0.372,
1.991
HIV Status+ 0.521 0.082,
3.319
HIV Status− 0.803 0.335,
1.925
N = 245
P values: *** ≥ 0.001; ** ≥ 0.01; * ≥ 0.05; + ≥ 0.1
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partners and lacking the means to obtain sufficient injec-
tion equipment seems to hold.
These findings support those of Kumar et al. [11] and
provide further evidence of complex dynamics in the so-
cial capital among PWID. We note that paying for a syr-
inge from a seller or receiving one free from the same
source, as well as finding one found on the street, are
the only syringe sources that do not require an add-
itional, non-financial resource—payment does not re-
quire relationships implied by other categories such as
friends, relatives, or even consistent “running partners”
(i.e., consistent co-users) or access to locations beyond
those necessary to obtain drugs. Ironically, in rural
Puerto Rico, social resources necessary to access safe in-
jection materials can be harder to obtain than simple
cash. Access to syringe exchange programs and
pharmacy-based sources necessitate a trip to a location,
or in the case of a mobile needle exchange, a consistent
pattern of location necessary to facilitate a meeting. Both
of these require time, means for communication (such
as a phone), and/or transportation. Receiving a syringe
from a friend or relative requires having a relationship
with a friend or relative who is willing to give you one
(rather than, say, just giving you the $1 necessary to pur-
chase one at the “punto” or drug purchase location).
Receiving a needle for free from a seller indicates the
presence of a relationship, but one that is clearly deter-
mined by the seller and not the PWID. In these ways, all
of the options other than obtaining a needle from a
seller (or finding one on the street—which is largely a
matter of chance) require some form of reliable non-
financial social capital.
What seems clear from the results shown here is that
the forms of social capital necessary to obtain safe injec-
tion equipment may run counter to the sorts of relation-
ships necessary to obtain other social resources,
especially regular and reliable sources of drug sharing
partners need to perform caballo [46]. For highly
heroin-dependent users, the frequent practice of caballo
normally requires maintaining a high number of co-
injection relationships—being available to others in
order to have them available to oneself—and finding a
ready partner when one is in danger of withdrawal. The
latter—a large network of potential caballo partners—is
thus a form of social capital, but not one that is normally
spoken of as such. Still, if social capital is the ability to
access resources, we must be open to the idea that dif-
ferent resource “fields,” in the worlds of Pierre Bourdieu
[62], may imply very different sorts of relationships. In
Table 6 Two-tailed binary logistic regression on needle source:
seller, paid
OR
(full)
CI *** OR
(condensed)
CI ***
Number of Injection
Partners
1.260 1.022,
1.552
* 1.308 1.068,
1.600
**
Married/cohab 0.767 0.400,
1.468
Income over $5000 1.251 0.634,
2.470
Male 1.440 0.598,
3.468
Age now 0.993 0.964,
1.023
Age, first injection 0.977 0.942,
1.012
Homeless, past year 1.443 0.801,
2.600
Injection frequency 0.932 0.671,
1.296
HCV status+ 1.241 0.609,
2.529
HCV Status− 1.214 0.541,
2.723
HIV Status+ 0.280 0.046,
1.712
HIV Status− 1.473 0.633,
3.426
N = 245
P values: *** ≥ 0.001; ** ≥ 0.01; * ≥ 0.05; + ≥ 0.1
Table 5 Two-tailed binary logistic regression on needle source:
seller, free
OR
(full)
CI *** OR
(condensed)
CI ***
Number of injection
partners
1.346 1.110,
1.632
** 1.346 1.104,
1.1642
**
Married/cohab 0.567 0.178,
1.804
Income over $5000 1.909 0.630,
5.782
Male 1.429 0.284,
7.197
Age now 0.963 0.920,
1.009
Age, first injection 0.986 0.911,
1.068
Homeless, past year 2.253 0.893,
5.686
+ 1.934 0.844, 4.429
Injection frequency 1.363 0.772,
2.404
HCV status+ 0.811 0.291,
2.262
0.663 0.257, 1.712
HCV status− 0.262 0.060,
1.150
+ 0.242 0.057, 1.022
HIV status+ 0.694 0.061,
7.851
+ 0.378 0.123, 0.927
HIV Status− 0.397 0.134,
1.175
0.338 0.110, 0.804
N = 245
P-values: *** ≥ 0.001; ** ≥ 0.01; * ≥ 0.05; + ≥ 0.1
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this case, the social effort to stave off the physical effects
of addiction seems to encourage relationships with
highly risky implications, and which do not easily trans-
late into relationships that promote access to safe injec-
tion equipment.
In this way, a high number of partners do not imply a
lack of overall social capital but a lack of the sort of so-
cial capital necessary to obtain sufficient safe injection
equipment. Highly networked/high-frequency users may
continue to rely on a combination of sources to get the
high volume of syringes needed for high rates of injec-
tion, and our results should not be read to indicate that
highly networked individuals rely entirely on unsafe
sources. Rather, our results show that only highly net-
worked users show a statistically significant tendency to
access high-risk sources, while less-networked users are
largely undifferentiated in their use of other sources.
Ethnographic research with this population shows that
all users prefer to obtain needles from an SEP, where
they can be guaranteed safe equipment that can be ob-
tained for free.
A focus on social capital shows us that multiple forms
of social capital are involved in the injection process,
and that, contrary to general theoretical suggestions by
Bourdieu [63] and practical suggestions by Lovell [61],
different forms of social capital may not be convertible
from one domain to another. Put another way, maintain-
ing a high number of partners necessary for caballo may
not contribute to having a high level of social support
for obtaining safe syringes. For highly networked/high-
frequency users, the sources of social capital necessary
to support safe injection are clearly less than the social
capital they maintain to perform caballo. Their inability
to convert one form of capital to the other (at sufficient
levels to inject safely) may elevate overall network risk of
transmitting injection-related pathogens. We feel that
such an understanding is more accurate than what is im-
plied by “negative” social capital.
Limitations
There are two key limitations to this study. First, we
have a relatively small dataset, which limits our predict-
ive power. Second, we lost as many as 43 respondents
from the overall sample, over 10% of our dataset, to
non-response on our dependent variables. However,
some of this is mitigated by our focus on comparison
between sources, as there were very few differences in
missing data between the six sources. In addition, our
study is limited in that it only asks if a respondent ac-
quired a syringe from a given source in the last year. It
may be beneficial to examine this type of question using
a scale, whereby a measure of use frequency for each
source is estimated by the respondents. Additional infor-
mation on perceived risk associated with each source
could provide insight into the actual conditions of the
syringes received. Had we asked respondents about their
preferences for sources, or the extent to which they
ranked their various options, such data could help estab-
lish the difference between individual choice and overall
social constraint on those choices. However, these needs
were not anticipated prior to data collection, and we did
not ask questions related to source preferences or a
ranking of choices.
While our missing data would typically be a very im-
portant limitation, the goal of this paper is to draw com-
parisons between those who use each source, and there
is little variation in missing data between sources. In
other words, almost anyone who failed to answer ques-
tions about using a single source typically failed to an-
swer about using all sources, meaning that comparisons
across sources therefore drew on nearly identical sam-
ples. One result of this listwise deletion, however, is that
differences found between those who use risky sources
and those who do not are potentially underestimated; it
is possible that the riskiest respondents were more likely
to refuse to answer these questions. For this reason, we
view the results of this analysis as a conservative esti-
mate of differences between acquisition classes.
Additional limits include the fact that we have no way
of knowing if any steps were taken prior to co-injection
that would decrease the likelihood of disease risk (e.g., if
syringes were cleaned prior to use). Taking steps like
these decrease risks associated with co-injection in a
way that is not measured when simply looking at the act
Table 7 Two-tailed binary logistic regression on needle
source: street
OR
(full)
CI *** OR
(condensed)
CI ***
Number of injection
partners
1.282 1.051,
1.563
* 1.289 1.092,
1.520
**
Married/cohab 0.374 0.040,
3.507
Income over $5000 0.618 0.069,
5.558
Age now 0.999 0.933,
1.070
Age, first injection 0.873 0.727,
1.049
Homeless, past year 0.772 0.175,
3.398
Injection frequency 0.775 0.341,
1.763
HIV Status+ 1.696 0.098,
29.391
HIV Status− 0.447 0.078,
2.547
N = 245
P values: *** ≥ 0.001; ** ≥ 0.01; * ≥ 0.05; + ≥ 0.1
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of sharing. Second, including a measure of how frequent
someone’s seller sells drugs could also potentially yield
interesting information about the nature of the seller/
user relationship through which the syringes associated
with Table 5 were obtained, providing important infor-
mation about this aspect of PWID social capital.
Conclusion
Our results show limited association between how many
injection partners someone has and whether or not they
acquire needles from exchange programs, pharmacies,
friends and relatives, from their sellers, or off the street.
There is evidence of a positive relationship between
obtaining a syringe from a seller, or off the street, and
having more injection partners. Our interpretation of
these findings centers on the fact that the latter are the
only sources that do not require non-monetary re-
sources, such as the sorts of social relationships implicit
in accessing syringes from a friend, pharmacy, or syringe
exchange. Obtaining a syringe from a seller only requires
money, which is already required to purchase drugs and
is co-located with that transaction. This suggests that fa-
cilitating the access of highly networked, high-frequency
injectors to safer sources of syringes such pharmacies
and syringe exchange providers can contribute to limit-
ing risk practices among this group, and that current
levels of secondary access via friends and co-injectors
are insufficient to meet these needs.
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